HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TFX
Teleflex Incorporated
TFX's fundamentals are mixed: its operating margin went from −7.5% to 9.4%, but revenue fell 29%. Its PE of 19x looks cheaper than it really is, because one-off gains boosted its recent earnings. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TFX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| Under pressure | |
| Under pressure |
TFX's profitability is currently healthy, but its revenue, cash flow and balance sheet are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TFX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $153 | — |
| Current | 19x | $153 | — |
| Cheap | 28x | $227 | +48% |
| Fair | 34x | $279 | +82% |
| Expensive | 49x | $404 | +164% |
Historical ranges are pointers, not guarantees.
TFX's PE is in its cheap range at 19x, but its recent earnings include one-off gains. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TFX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TFX's earnings to grow and its profitability to improve, but its revenue to decline.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TFX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.93 | +21% |
| Q3 2026 | $8.23 | +$15.52 |
| Q2 2026 | -$23.29 | -640% |
| Q1 2026 | -$22.80 | -806% |
| Q4 2025 | -$20.55 | -1489% |
| Q3 2025 | -$7.29 | -245% |
| Q2 2025 | $4.31 | -23% |
| Q1 2025 | $3.23 | -48% |
| Q4 2024 | $1.48 | -80% |
TFX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TFX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TFX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $567.8M | -38% |
| Q2 2026 | $570.3M | -27% |
| Q1 2026 | $548.3M | -22% |
| Q4 2025 | $569M | -28% |
| Q3 2025 | $913M | +19% |
| Q2 2025 | $780.9M | +4.2% |
| Q1 2025 | $700.7M | -5% |
| Q4 2024 | $795.4M | +2.8% |
TFX's revenue has slid since its 2025 peak: $568M last quarter, down 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +63 points |
| Q2 2026 | 13% | -7.1 points |
| Q1 2026 | 3.7% | -14 points |
| Q4 2025 | 2.4% | +16 points |
| Q3 2025 | -45% | -64 points |
| Q2 2025 | 20% | +4.3 points |
| Q1 2025 | 18% | +19 points |
| Q4 2024 | -14% | -25 points |
TFX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TFX on cash flow, with more consistent year-over-year improvement.
TFX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $74.7M | -4.1% |
| Q2 2026 | $77.9M | +$104.6M |
| Q1 2026 | $27.9M | -36% |
| Q4 2025 | -$92.9M | -154% |
| Q3 2025 | $77.8M | -63% |
| Q2 2025 | -$26.8M | -147% |
| Q1 2025 | $43.3M | -42% |
| Q4 2024 | $170.6M | +53% |
TFX still generates free cash flow, though less than at its 2024 peak: $87M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TFX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TFX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.7% | -2M shares |
| 1 year | -5.9% | -2.6M shares |
| 3 years | -12% | -5.7M shares |
| 5 years | -12% | -5.8M shares |
| Available history | -12% | -5.5M shares |
TFX has 42M diluted shares, down 5.9% from a year ago, with $555M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $305M |
| Q2 2026 | $250M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $300M |
| Q4 2024 | — |
TFX spent $555M buying back its own shares over the past year, up 85% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TFX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.6x | Elevated |
| Q4 2025 | 35.6x | High |
| Q3 2025 | 52.2x | High |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 2.9x | Moderate |
| Q4 2024 | 3.2x | Elevated |
| Q3 2024 | 2.5x | Moderate |
| Q2 2024 | 2.4x | Moderate |
TFX's net debt is about 3.6 years of its operating earnings (EBITDA), up from 2.9 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TFX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.4 | Neutral |
| Stochastic | 85.3 | Overbought |
TFX's weekly RSI is 68 (neutral) and its Stochastic is 85 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TFX PE vs Healthcare Sector
| Metric | TFX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 1 | 29 | 28 pts below |
TFX is trading at 19x earnings, a 28% discount to the Healthcare sector's median of 26x, though its recent earnings include one-off gains.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TFX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $135.2 | 13% above |
| 20 week MA | $135.0 | 13% above |
| 50 week MA | $125.9 | 22% above |
| 100 week MA | $130.4 | 17% above |
| 200 week MA | $179.2 | 15% below |
TFX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TFX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $372.0 | $405.1 | +8.9% |
| 2021 | $405.1 | $327.4 | -19% |
| 2022 | $327.4 | $248.8 | -24% |
| 2023 | $248.8 | $249.3 | +0.2% |
| 2024 | $249.3 | $179.5 | -28% |
| 2025 | $179.5 | $122.8 | -32% |
| 2026 YTD | $122.8 | $153.2 | +25% |
TFX has the edge over HIMS on returns for 2026, with the stronger performance.